Senior Managing Partner & CEO, Flagship Pioneering
Unknown.png

CATHERINE A. SOHN, PHARM.D.

Adjunct Professor, University of California San Francisco


Catherine Angell Sohn, Pharm.D., is a pharmacist, adjunct professor, global biopharmaceutical and consumer healthcare executive, and serves on the Boards of life science companies. She is an independent Director on the Board of Directors of Jazz Pharmaceuticals (NASDAQ: JAZZ), Rubius Therapeutics (NASDAQ: RUBY), and Landec Corp (NASDAQ: LNDC), and is Chairman of BioEclipse Therapeutics, Inc, an early, clinical stage biotechnology company (private). She holds the position of Adjunct Professor at the University of California, San Francisco, School of Pharmacy, and is a member of the Investment Committee of Pennsylvania’s Ben Franklin Technology Partners. 

Dr. Sohn has deep biopharmaceutical industry knowledge with thirty years of global experience. Her areas of expertise include strategic product development, business development, commercial operations and introduction of new vaccines, pharmaceutical products and consumer healthcare brands. She started the US Vaccine Business and led the launch of SmithKline Beecham plc’s (now GlaxoSmithKline) first vaccine in the US. Sohn was vice president for worldwide strategic product development from 1994 – 1998, for the cardiovascular, pulmonary and metabolic therapeutic areas at SB plc where she was responsible for product strategy, valuation and strategic commercial leadership of assets from Phase 1 through global life cycle management. Until retiring from GlaxoSmithKline plc, she was senior vice president for business development and a member of the global executive team in the GSK’s Consumer Healthcare division, responsible for global, US, Japanese and European licensing agreements and acquisitions (1998 – 2010).

Sohn earned a Doctor of Pharmacy (Pharm.D.) degree from the University of California San Francisco and a certificate of professional development from The Wharton School at the University of Pennsylvania. She is an NACD (National Association of Corporate Directors) Board Leadership Fellow and a Certified Licensing Professional (CLP).